Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.43 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.43 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.43 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15172491 | 1.00 | RAB9A (0.56) | RAB9AALDH1A1TSHRCYP3A4SMN1; SMN2 | |
| SCHEMBL14856021 | 0.96 | ALDH1A1 (0.54) | RAB9AALDH1A1TSHRCYP3A4SMN1; SMN2 | |
| SCHEMBL14855597 | 0.96 | ALDH1A1 (0.54) | RAB9AALDH1A1TSHRCYP3A4SMN1; SMN2 | |
| SCHEMBL5568155 | 0.86 | MAPK1 (0.56) | RAB9AALDH1A1SMN1; SMN2KDM4ERECQL | |
| SCHEMBL2399329 | 0.86 | MMP2 (0.51) | ALDH1A1SMN1; SMN2KDM4ERECQLPSEN1 | |
| SCHEMBL5518996 | 0.86 | MMP2 (0.51) | ALDH1A1SMN1; SMN2KDM4ERECQLPSEN1 | |
| SCHEMBL5568161 | 0.86 | MAPK1 (0.56) | RAB9AALDH1A1SMN1; SMN2KDM4ERECQL | |
| SCHEMBL1876072 | 0.86 | ALDH1A1 (0.51) | RAB9AALDH1A1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL1877899 | 0.86 | ALDH1A1 (0.51) | RAB9AALDH1A1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL14855976 | 0.85 | BACE1 (0.47) | RAB9AALDH1A1SMN1; SMN2LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5672598-A | MATRIX METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 1997-09-30 | — | — | US | claimed |
| US-10613105-B2 | Competitive immunoassay test system for detecting a pyrogen | FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) | 2020-04-07 | — | — | US | disclosed |
| EP-3020824-B1 | COMPETITIVE IMMUNOASSAY TEST SYSTEM FOR DETECTING A PYROGEN | FRAUNHOFER GES FORSCHUNG (DE) | 2017-11-08 | — | — | EP | disclosed |
| US-20160327580-A1 | COMPETITIVE IMMUNOASSAY TEST SYSTEM FOR DETECTING A PYROGEN | FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) | 2016-11-10 | — | — | US | disclosed |
| EP-3020824-A1 | COMPETITIVE IMMUNOASSAY TEST SYSTEM FOR DETECTING A PYROGEN | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2016-05-18 | — | — | EP | disclosed |
| US-20130203734-A1 | ANTI-INFLAMMATORY AGENTS | GRAINGER DAVID JOHN (GB) | 2013-08-08 | — | — | US | disclosed |
| EP-1496877-B1 | METHOD AND COMPOSITION FOR TREATMENT OF DIABETES, HYPERTENSION, CHRONIC HEART FAILURE AND FLUID RETENTIVE STATES | NOVO NORDISK AS (DK) | 2008-10-01 | — | — | EP | disclosed |
| EP-1404675-B1 | DPP-IV-INHIBITING PURINE DERIVATIVES FOR THE TREATMENT OF DIABETES | NOVO NORDISK AS (DK) | 2008-03-12 | — | — | EP | disclosed |
| US-20070197552-A1 | Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states | NOVO NORDISK A/S (DK) | 2007-08-23 | — | — | US | disclosed |
| US-7192952-B2 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | NOVO NORDISK, A/S (DK) | 2007-03-20 | — | — | US | disclosed |
| EP-1404675-A1 | DPP-IV-INHIBITING PURINE DERIVATIVES FOR THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2004-04-07 | — | — | EP | disclosed |
| US-20030236272-A1 | Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states | NOVO NORDISK A/S (DK) | 2003-12-25 | — | — | US | disclosed |
| EP-0815084-B1 | LACTAM-CONTAINING HYDROXAMIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MATRIX METALLOPROTEASE | PROCTER & GAMBLE (US) | 2003-08-27 | — | — | EP | disclosed |
| WO-2003057200-A2 | COMPOSITIONS COMPRISING INHIBITORS OF DPP-IV AND NEP ENZYMES FOR THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2003-07-17 | — | — | WO | disclosed |
| US-20030105077-A1 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2003-06-05 | — | — | US | disclosed |
| WO-2003004496-A1 | DPP-IV-INHIBITING PURINE DERIVATIVES FOR THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2003-01-16 | — | — | WO | disclosed |
| US-5672598-A | MATRIX METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 1997-09-30 | — | — | US | disclosed |
| US-5527777-A | TREATMENT OF PROSTATE CANCER, ANTIFERTILITY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-06-18 | — | — | US | disclosed |
| EP-0668874-A1 | LHRH ANTAGONISTS AND INTERMEDIATE PRODUCTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-08-30 | — | — | EP | disclosed |
| WO-1992020711-A2 | LHRH ANTAGONISTS AND INTERMEDIATE PRODUCTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203734-A1 | ANTI-INFLAMMATORY AGENTS | IL6, TNF, IL1B | RAB9A 3261/4885ALDH1A1 178/4885TSHR 4649/4885 |
| US-20030105077-A1 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | DPP4, DPP7, DPP3 | RAB9A 4471/4885ALDH1A1 55/4885TSHR 3634/4885 |
| US-20030236272-A1 | Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states | DPP4, GIPR, GLP1R | RAB9A 2919/4885ALDH1A1 2283/4885TSHR 918/4885 |
| US-20070197552-A1 | Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states | DPP4, GIPR, GLP1R | RAB9A 2919/4885ALDH1A1 2283/4885TSHR 918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.